Skip to main content

Day: June 28, 2023

ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity

Lupus Nephritis (“LN”) is characterized by inflammation in the kidney, protein leakage into the urine (“proteinuria”), and progressive kidney damage NLRP3 inflammasomes were extensively activated in the kidneys of LN patients, with higher levels of activation in patients with more severe forms of the disease Inflammasome activation was positively correlated with clinicopathological indices of LN ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammationWESTON, Fla., June 28, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal...

Continue reading

Synlogic Announces International Nonproprietary Name Selection for SYNB1934

The World Health Organization has approved “labafenogene marselecobac” Name attributes recognize Synlogic’s proprietary technology and commitment to phenylketonuria community CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has selected “labafenogene marselecobac” for the nonproprietary name of the company’s investigational drug for phenylketonuria (PKU), previously known as SYNB1934. Naming attributes recognize Synlogic’s proprietary technology and the company’s deep appreciation for, and commitment to, the PKU community. Labafenogene...

Continue reading

First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

Topline data expected in July 2023 BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the final patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). The Phase 2 multi-center clinical trial (NCT05719311) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving thirteen (13) patients. The...

Continue reading

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas

KNOXVILLE, TN, June 28, 2023 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with the University of Tennessee College of Veterinary Medicine (UTCVM) to assess the safety and preliminary efficacy of intralesional injection of a formulation of Provectus’s pharmaceutical-grade RBS for canine soft tissue sarcomas. UTCVM’s lead principal investigator of this work is clinical pathologist, comparative cancer biologist, and Assistant Professor Nora Springer, DVM, PhD, DACVP. This preclinical and clinical veterinary study is being undertaken as part of the State of Tennessee’s funding to develop animal health drug products in partnership with state universities that have agriculture and veterinary medicine programs and the Company. Soft tissue sarcomas are common...

Continue reading

GXO Schedules Second Quarter Earnings Conference Call for Thursday, August 3, 2023

GREENWICH, Conn., June 28, 2023 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO) will hold its second quarter conference call and webcast on Thursday, August 3, 2023, at 8:30 a.m. Eastern Time. The company’s results will be released after market close on Wednesday, August 2, 2023, and made available at that time on investors.gxo.com. Access information: Call toll-free from U.S./Canada: 877-407-8029International callers: +1 201-689-8029Conference ID: 13739294Live webcast: investors.gxo.com A replay of the conference call will be available for approximately two weeks, until August 17, 2023, by calling toll-free (from U.S./Canada) 877-660-6853; international callers dial +1 201-612-7415. Use the passcode 13739294. About GXO Logistics GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and...

Continue reading

Paramount Gold Provides Permitting Update For Its Proposed High Grade Underground Grassy Mountain Gold Mine

Permitting Progresses at All Levels of Government WINNEMUCCA, Nev., June 28, 2023 (GLOBE NEWSWIRE) — Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) announced today that it has received approval for a two-year extension of its Conditional Use Permit during a public meeting of the Malheur County Planning Department held on June 22nd. The Company is also pleased to report that it has submitted all responses and additional information requested by Oregon State permitting agencies which they require to determine if the Company’s Consolidated Permit Application (“CPA”) is complete. These submissions address aspects of the CPA that the State deemed necessary to advance to the Notice to Proceed (the “Notice”) stage of the permitting process. The Notice initiates the 225 days of draft permit writing by State...

Continue reading

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

– Clinical data support safety and tolerability profile of FHD-286, a highly potent, – selective, allosteric, oral, small molecule inhibitor of BRG1/BRM – Clinical activity observed in late-line metastatic uveal melanoma includes nine patients with stable disease and one patient with a confirmed partial response – Foghorn does not plan to advance FHD-286 in uveal melanoma – Foghorn anticipates initiating a FHD-286 combination study in relapsed/refractory AML during the third quarter of 2023 CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced data from the Phase 1 dose escalation safety study of FHD-286...

Continue reading

Boralex ranks once again among Corporate Knights’ Best 50 Corporate Citizens in Canada

MONTREAL, June 28, 2023 (GLOBE NEWSWIRE) — Boralex inc. (“Boralex” or the “Company”) (TSX: BLX) is pleased to announce that it has been once again named one of Canada’s “Best 50 Corporate Citizens” by Corporate Knights, a sustainable economy magazine. Since 2002, this ranking has recognized companies for their leadership in sustainability. Last year, Boralex ranked 23rd; this year, the Company moved up into 21st place. To determine the ranking for 2023, Corporate Knights analysed 286 large Canadian organizations against Canadian and global industry peers on a suite of 25 quantitative key performance indicators1. Boralex excelled on five indicators:Carbon Productivity Sustainable Revenue Sustainable Investment CEO-Average Worker Pay Non-male Board“At Boralex, we know that climate risk is the biggest business risk of the...

Continue reading

Solaris Reports 54m of 0.80% CuEq from Surface in Northwest Step-Out at Warintza Central; 268m of 0.60% CuEq within 830m averaging 0.50% CuEq in Northeast Step-Out

Figure 1 – Plan View of Warintza Central Drilling Released to Date Figure 1 – Plan View of Warintza Central Drilling Released to DateVANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) — Solaris Resources Inc. (TSX: SLS; OTCQB: SLSSF) (“Solaris” or the “Company”) is pleased to report assay results from a series of holes aimed at growing the ‘Indicative Starter Pit’ within the Warintza Central zone at its Warintza Project (“Warintza” or the “Project”) in southeastern Ecuador. Highlights are listed below, with a corresponding image in Figure 1 and detailed results in Tables 1-2. HighlightsMineral resource expansion drilling continues to target growth of the ‘Indicative Starter Pit’, an area of near surface, high-grade mineralization estimated at 180 Mt at 0.82% CuEq¹ (Indicated) and 107 Mt at 0.73% CuEq¹ (Inferred) in...

Continue reading

Consolidated Uranium Commences Drilling and Reopening of the Underground at the Tony M Mine

Figure 1 Map of Tony M Mine outlining underground workings and planned drill locations for 2023 workFigure 2 Picture of drill rig being set up at the Tony M Mine for the 2023 programTORONTO, June 28, 2023 (GLOBE NEWSWIRE) — Consolidated Uranium Inc. (“CUR”, the “Company”, “Consolidated Uranium”) (TSXV: CUR) (OTCQX: CURUF) is pleased to announce the commencement of comprehensive work programs at CUR’s 100%-owned Tony M Mine (“Tony M”) in southeastern Utah. Tony M is one of three past producing uranium mines in Utah owned by CUR, and is a large-scale, fully developed and permitted underground mine that produced nearly one million pounds of U3O8 during two different periods of operation from 1979-1984 and from 2007-2008. The work programs being initiated follow key recommendations highlighted by SLR International Corporation...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.